A number of diseases tend to peak in the winter, thanks to indoor gatherings that help germs spread. The list includes not ...

GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) ...

According to DataM Intelligence, the Respiratory Syncytial Virus (RSV) Market Size reached USD 1.95 billion in 2024 and is projected to advance to USD 4.54 billion by 2033, expanding at a strong CAGR ...

Research led by the Veterans Affairs Portland Health Care System in Portland, Oregon, found that a single dose of respiratory ...

Guidelines recommend a single dose of RSV vaccine for older adults, but long-term data on the duration of protection is limited. In this study of U.S. veterans, effectiveness slid from over 80% in the ...

Researchers found differences in how respiratory syncytial virus spreads among children in rural versus urban communities and concluded that year-round immunizations would minimize risks of large ...

Anti-vaccine sentiment is alive and well, especially in the U.S. And it was evident in recent weeks as drugmakers revealed their third-quarter earnings, replete with declining vaccine sales. Pfizer’s ...

RSV vaccines showed initial high effectiveness, but protection decreased over 18 months, especially in immunocompromised individuals. The study used VHA data to evaluate vaccine effectiveness in ...

The season of never-ending sneezing and stuffy noses is underway, sending Americans to pharmacy lines in hopes of keeping illness at bay with yearly shots. While flu and COVID-19 vaccines are an ...

CAMBRIDGE, MA / ACCESS Newswire / November 20, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it has closed a five-year term loan facility for up to $1.5 billion of capital from Ares Management ...

Moderna told investors that it still thinks it can stop losing money in 2028, and that its financial outlook remains strong, but that it had taken out a $1.5 billion loan to shore up its balance sheet ...